PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation

Inclusion Criteria: * Diagnosis of * acute leukemia in complete remission, or * myelodysplasia with \<5% blasts, or * myeloproliferative neoplasm/myelofibrosis with \<5% marrow or circulating blasts * chemosensitive Hodgkin or non-Hodgkin lymphoma * Age 18 years or older * Performance status of ≥ 80% Karnofsky * Adequate organ function within 28 days of study registration defined as: * left ventricular ejection fraction ≥ 45% * pulmonary function with FEV1, FVC, and DLCO ≥ 50% predicted * AST and ALT \< 2 times upper limit of normal * Total bilirubin \<1.5 times the upper limit of normal. If the patient is suspected of having Gilbert syndrome, they require prior approval of the medical monitor * creatinine clearance ≥ 50cc/min * no active/uncontrolled infection * negative HIV, HBV and HCV * ferritin \< 2000 ng/ml * Patients able to tolerate oral medication * Women of childbearing potential and men with partners of child-bearing potential must agree to use of contraception for the duration of treatment through 60 days after the last treatment of VIC-1911 or sirolimus * Able to provide written voluntary consent prior to the performance of any research related tests or procedures Exclusion Criteria: * HCT-CI \> 4 or unable to receive myeloablative TBI * Use of planned post-transplant maintenance therapy to begin prior to day +75. Patients may receive standard of care maintenance therapies starting at day +75 or later * Patients with a history of h…